Cnsc-15. Duration And Timing Analysis Of Tumor Treating Fields (Ttfields) Therapy For Newly Diagnosed High-Grade Glioma Patients: A Real-World Retrospective Study In Two Centers
Chun Wang,Lingchao Chen,Jianxiong Ji,Junyan Zhang,Kun Song,Yanhong Pan,Nainai Ma,Huijuan Zheng,Yang Xiao,Gao Chen,Fuyi Liu,Zhiyong Qin
DOI: https://doi.org/10.1093/neuonc/noae165.0171
2024-11-29
Neuro-Oncology
Abstract:In the EF-14 phase 3 trial, tumor treating fields (TTFields) plus temozolomide improved progression-free and overall survival versus temozolomide alone in newly diagnosed glioblastoma. However, the optimal duration and timing of TTFields treatment have not been reported yet. In this study, we aimed to analyze the relationship between the timing of TTFields use, the total duration of therapy, and daily compliance with overall survival in high-grade glioma (HGG) and, therefore, provided detailed suggestions for clinical use of TTFields. A total of 343 patients were screened retrospectively after resection or biopsy at two centers and received TTFields treatment from April 2019 to April 2023. All the patients were re-evaluated based on the 2021 WHO CNS5 Classification. We collected clinical data, including basic clinical information, pathology, surgery, radiotherapy, and TTFields. Follow-up for survival was performed for all patients in December 2023, and another follow-up is planned for June 2024. After excluding non-HGG or lacking critical diagnostic information, 308 patients were included. Of these, 264 were Glioblastoma, IDH-wildtype, 27 were Astrocytoma, IDH-mutant, 3 were Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted, and 14 were Diffuse midline glioma, H3 K27-altered, or Diffuse hemispheric glioma, H3 G34-mutant. Baseline characteristics were listed below: median age was 53 years; 56.82% male; median baseline KPS was 90; 75.97% underwent gross total resection; 51.30% received chemoradiation with concurrent TTFields. Only 26.30% of patients were still using TTFields by December 31, 2023. The median time difference between TTFields and surgery was 55.5 days. The overall TTFields median duration was 334 days, with a median compliance rate of 85%. By December 31, 2023, 59.09% of the patients were still alive. The study group will continue to follow up on patients' survival. Further analysis of the correlation between treatment duration, compliance or timing and survival will be performed.
oncology,clinical neurology